Laurberg Peter, Andersen Stig, Karmisholt Jesper
a Aalborg Hospital, Århus University Hospital, Department of Endocrinology and Internal Medicine, Postboks 561, 9100 Aalborg, Denmark.
b Aalborg Hospital, Århus University Hospital, Department of Endocrinology and Internal Medicine, Postboks 561, 9100 Aalborg, Denmark.
Expert Rev Endocrinol Metab. 2006 Jan;1(1):91-102. doi: 10.1586/17446651.1.1.91.
Only a minority of patients with hyperthyroidism caused by Graves' disease will experience cure of disease with a permanent euthyroid state without medication. Antithyroid drugs are useful in attaining euthyroidism, and most patients will gradually enter remission of the autoimmune abnormality after becoming euthyroid. A stable euthyroid state may be sustained by prolonged low-dose medication. The risk of relapse of hyperthyroidism after withdrawal of medication seems to be independent of duration of therapy, once remission has been induced. A number of risk factors influence the outcome of therapy and they should be evaluated when planning duration of therapy with antithyroid drugs.
仅有少数由格雷夫斯病引起的甲状腺功能亢进患者在未用药的情况下可实现疾病治愈并维持永久性甲状腺功能正常状态。抗甲状腺药物有助于实现甲状腺功能正常,大多数患者在甲状腺功能正常后会逐渐进入自身免疫异常缓解期。通过长期低剂量用药可维持稳定的甲状腺功能正常状态。一旦诱导缓解,停药后甲状腺功能亢进复发的风险似乎与治疗持续时间无关。许多风险因素会影响治疗结果,在规划抗甲状腺药物治疗疗程时应予以评估。